Clinical pharmacokinetics of Kemantane in bronchial disease
Study involving people · 1991
- What was studied
- Patients with bronchial disease. Enrollment was not stated in the abstract.
- Main finding
- Gas–liquid chromatography detected little parent compound in blood. The authors attributed this to first-pass metabolism and characterized exposure using the principal active metabolite.
Reported findings and study design
Findings described in words
Gas–liquid chromatography in patients with bronchial disease.
Population or model Patients with bronchial disease. Enrollment was not stated in the abstract.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Parent compound in blood | Little or no detectable parent Kemantane. The authors evaluated exposure through its major active metabolite. |
The abstract provides no numerical estimates, dose, sampling schedule or group sizes.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- The abstract does not provide the dose, sampling schedule or numerical pharmacokinetic estimates. This report assesses exposure.
Source details
Indexed English abstract of the original Russian journal report.
Sources checked
Citation
S. S. Boiko, V. P. Zherdev, N. A. Kisliak. Clinical pharmacokinetics of Kemantane in bronchial disease Farmakol Toksikol. 1991;54(1):57–59.